Our mission is to combat dysbiosis* in the human body.

To that end, we aim to commercialize antimicrobial peptide therapies to safely restore balance to the gut’s microbial flora and overcoming disease.

Beginning with our gingivitis indication, we will work our way down the gastrointestinal (GI) tract, addressing conditions including small intestinal bacterial overgrowth (SIBO) and irritable bowel syndrome (IBS) by correcting the underlying dysbiosis that drives pathology.

P4 Microbiome was founded by Johns Hopkins University professors Phillip Phan and Jay Pasricha. The company took over the clinical development of P4M01 from the US Army in February of 2020.

Together they recognized the immense potential of this discovery, not only for oral health, but also for solving dysbiosis in the GI tract.

*Dysbiosis: A change in the microbial composition, especially in the GI tract, that causes imbalance between beneficial and potentially pathogenic bacteria.